SPOTLIGHT -
Outlook Therapeutics reports positive clinical results for bevacizumab for wet AMD
Outlook Therapeutics completes Phase 3 NORSE TWO safety and efficacy trial for ONS-5010, an investigational ophthalmic formulation of bevacizumab for treatment of wet AMD.
Read More
Is there space for telehealth within retina specialty?
Mark Breazzano, MD, discusses the future of telehealth for retina specialists.
Aldeyra Therapeutics's ADX-2191 receives orphan drug designation from FDA
The U.S. FDA granted orphan drug designation to ADX-2191, methotrexate for intravitreal injection, as treatment for retinitis pigmentosa.
FDA accepts Genentech’s BLA for faricimab for treatment of wet AMD and DME
If approved, Genentech’s treatment of faricimab will be the first and only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.
ASCRS conference overview for retina specialists
The American Society of Cataract and Refractive Surgery hosted its 2021 ASCRS and ASOA Annual Meeting July 23-27 in Las Vegas, Nevada.
How has the COVID-19 pandemic affected daily practice for retina specialists?
Mark Breazzano, MD, discusses the effects of the COVID-19 pandemic on daily practice for retina specialists.
UV safety month poll: Have you treated UV-related eye conditions this year?
A poll for ophthalmologists and retina specialists to celebrate UV Safety Month. This poll will close July 28, 2021.
Fireworks and eye injuries: how to stay safe during Independence Day celebrations
As the Fourth of July approaches, ophthalmologists warn patients to exercise caution with fireworks.
Fireworks and eye safety poll: Which injuries do ophthalmologists see most often?
A survey of fireworks-related injuries for ophthalmologists and retina specialists.